Form 4: Lemaitre Vascular Director Sells Shares After PSU Vesting

Lemaitre Vascular's President and Director, David B. Roberts, reported the acquisition of common stock from vested performance share units and subsequent sale of 8,464 shares.

Summary

• David B. Roberts, President and Director of Lemaitre Vascular Inc. (LMAT), reported multiple transactions.
• On February 26, 2026, Roberts acquired 1,514 shares of LMAT common stock from the settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. This award vested 25%, with the remainder vesting in equal annual installments over the next three years.
• Also on February 26, 2026, Roberts acquired 146 shares of LMAT common stock from the settlement of another PSU award granted on February 18, 2025. This award also vested 25%, with the balance vesting in equal annual installments on December 6th over the next three years (2026, 2027, 2028).
• An additional 3 shares were acquired on February 26, 2026, upon the release of dividend equivalent rights.
• To cover tax withholding obligations related to the PSU vestings, Roberts disposed of 134 shares (from the 2024 PSU) and 13 shares (from the 2025 PSU) at a price of $113.69 per share. These were exempt sales under Rule 16b-3(e).
• On February 27, 2026, Roberts sold 8,464 shares of LMAT common stock at a weighted average price of $106.8003, with individual trades ranging from $105.85 to $107.30.
• Following these transactions, Roberts beneficially owns 17,979 shares of LMAT common stock directly.
• 9.38 dividend equivalent rights remain beneficially owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While there's an insider sale, it follows the vesting of equity awards and includes tax-related dispositions, which are routine for executive compensation.

Positives

• Vesting of Performance Share Units (PSUs) indicates the achievement of performance conditions, leading to the acquisition of 1,514 shares and 146 shares of common stock.
• Acquisition of 3 shares from dividend equivalent rights.

Negatives

• Sale of 8,464 shares of common stock by a director and president, which could be interpreted as a reduction in insider confidence, although it may be for personal liquidity or portfolio diversification.
• Disposal of 147 shares (134 + 13) to satisfy tax withholding obligations, reducing the net shares received from PSU vesting.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported in a Form 4, are routine disclosures for publicly traded companies. While the sale of shares by a director and president can sometimes be viewed with caution, it is often part of pre-arranged trading plans (Rule 10b5-1) or for personal financial planning, especially following the vesting of equity compensation. This filing reflects standard compensation and liquidity events for a senior executive.

Related Party Transactions

• Acquisition of 1,514 shares of common stock from Lemaitre Vascular Inc. upon settlement of a PSU award.
• Acquisition of 146 shares of common stock from Lemaitre Vascular Inc. upon settlement of a PSU award.
• Acquisition of 3 shares of common stock from Lemaitre Vascular Inc. upon release of dividend equivalent rights.
• Disposal of 134 shares to Lemaitre Vascular Inc. for tax withholding obligations.
• Disposal of 13 shares to Lemaitre Vascular Inc. for tax withholding obligations.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived negatively, but the overall impact is likely minimal as it's a routine insider transaction. The reduction in direct beneficial ownership by a key executive might slightly alter the alignment of interests, but the remaining holding is still substantial.

Next Steps

• Balance of PSU awards granted on December 6, 2024, will vest in equal annual installments over the next three years.
• Balance of PSU awards granted on February 18, 2025, will vest in equal annual installments on December 6th over the next three years (2026, 2027, and 2028).

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation and personal liquidity. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider activity.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Trading, Stock Sale, Performance Share Units, PSU Vesting, Director Transaction, Officer Transaction, Equity Compensation, David B. Roberts